ScoreComparison
Why is Immuno-Biological Laboratories Co., Ltd. ?
1
Poor Management Efficiency with a low ROE of 6.24%
- The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
2
Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.88
- Poor long term growth as Net Sales has grown by an annual rate of 11.40% over the last 5 years
- Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -8.88
- The company has been able to generate a Return on Equity (avg) of 6.24% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of 11.40% over the last 5 years
4
Positive results in Jun 26
- INTEREST COVERAGE RATIO(Q) Highest at 39,950.65
- RAW MATERIAL COST(Y) Fallen by -8.33% (YoY)
- CASH AND EQV(HY) Highest at JPY 1,897.41 MM
5
With ROE of 20.33%, it has a attractive valuation with a 5.07 Price to Book Value
- Over the past year, while the stock has generated a return of 85.40%, its profits have risen by 19.8% ; the PEG ratio of the company is 1.3
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Immuno-Biological Laboratories Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Immuno-Biological Laboratories Co., Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Immuno-Biological Laboratories Co., Ltd.
96.06%
0.74
114.08%
Japan Nikkei 225
60.14%
2.04
29.37%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
11.40%
EBIT Growth (5y)
20.91%
EBIT to Interest (avg)
81.51
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.55
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
16.98%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
14.71%
ROE (avg)
6.24%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
25
Industry P/E
Price to Book Value
5.07
EV to EBIT
26.73
EV to EBITDA
25.22
EV to Capital Employed
7.81
EV to Sales
7.98
PEG Ratio
1.26
Dividend Yield
NA
ROCE (Latest)
29.24%
ROE (Latest)
20.33%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bearish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend12What is working for the Company
INTEREST COVERAGE RATIO(Q)
Highest at 39,950.65
RAW MATERIAL COST(Y)
Fallen by -8.33% (YoY
CASH AND EQV(HY)
Highest at JPY 1,897.41 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 5.4 times
NET SALES(Q)
Highest at JPY 286.01 MM
OPERATING PROFIT(Q)
Highest at JPY 122.25 MM
OPERATING PROFIT MARGIN(Q)
Highest at 42.74 %
PRE-TAX PROFIT(Q)
Highest at JPY 120.15 MM
NET PROFIT(Q)
Highest at JPY 111.22 MM
-2What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -39 %
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.79 times
Here's what is working for Immuno-Biological Laboratories Co., Ltd.
Interest Coverage Ratio
Highest at 39,950.65
in the last five periodsMOJO Watch
The company's ability to manage interest payments is improving
Operating Profit to Interest
Net Sales
Highest at JPY 286.01 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Net Sales
At JPY 286.01 MM has Grown at 13.84%
over average net sales of the previous four periods of JPY 251.25 MMMOJO Watch
Near term sales trend is positive
Net Sales (JPY MM)
Operating Profit
Highest at JPY 122.25 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Operating Profit Margin
Highest at 42.74 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at JPY 120.15 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Pre-Tax Profit
At JPY 120.15 MM has Grown at 62.88%
over average net sales of the previous four periods of JPY 73.76 MMMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (JPY MM)
Net Profit
Highest at JPY 111.22 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (JPY MM)
Cash and Eqv
Highest at JPY 1,897.41 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 5.4 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Raw Material Cost
Fallen by -8.33% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Immuno-Biological Laboratories Co., Ltd.
Debt-Equity Ratio
Highest at -39 %
in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
Inventory Turnover Ratio
Lowest at 0.79 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
